David G. Maloney

Universität Hamburg — Germany

Medicine · Health Sciences

110h-index52.9kcitations838works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(362), Lymphoma Diagnosis and Treatment(233), Hematopoietic Stem Cell Transplantation(211), Chronic Lymphocytic Leukemia Research(168), Immune Cell Function and Interaction(85)

Publications836 total

Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation
Bone Marrow Transplantation·2026Open Access
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
Blood·2025Open Access
535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
Regular and Young Investigator Award Abstracts·2025Open Access
585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Regular and Young Investigator Award Abstracts·2025Open Access
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
Transplantation and Cellular Therapy·2025· 1 cited
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology·2025· 4 citedOpen Access
P3.18.87 EVEREST-2: Phase 1/2 Study of Logic-Gated Tmod CAR T A2B694 in Lung Cancer and Other Tumors Expressing MSLN With HLA-A*02 LOH
Journal of Thoracic Oncology·2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
Transplantation and Cellular Therapy·2025· 1 cited
0434 Clinical and translational data from a first-in-human study of a novel precision cellular immunotherapy (DSG3-CAART) in mucosal pemphigus vulgaris
Journal of Investigative Dermatology·2025· 1 cited
139 | ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025· 1 citedOpen Access
EVEREST-1: Safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
Journal of Clinical Oncology·2025· 2 cited
EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
Journal of Clinical Oncology·2025· 2 cited
BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine clinical trials.
Journal of Clinical Oncology·2025
Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
Journal of Clinical Oncology·2025· 2 cited
Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Cancer Research·2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
Blood·2025· 2 citedOpen Access
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Haematologica·2025· 3 citedOpen Access
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Blood·2025· 14 cited
Supplementary Figure 3 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
2025Open Access
Supplementary Figure 2 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
2025Open Access
page 1 of 42Next →

Frequent Co-authors

Rainer Storb(19), Brenda M. Sandmaier(17), Michael B. Maris(14), Stanley R. Riddell(14), Barry E. Storer(13), Cameron J. Turtle(13), Mohamed L. Sorror(11), Sindhu Cherian(8), Thomas R. Chauncey(8), Frederick R. Appelbaum(8), Xueyan Chen(7), Kevin A. Hay(7), Daniel Li(6), Peter A. McSweeney(6), Karl G. Blume(6), Paul J. Martin(6), Brent L. Wood(5), Dietger Niederwieser(5), Mary E.D. Flowers(5), Oliver W. Press(5)